Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

AGIO 10.17.2024

Full Press ReleaseSEC FilingsOur AGIO Tweets

About Gravity Analytica

Recent News

  • 03.03.2025 - TD Cowen 45th Annual Healthcare Conference
  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.07.2025 - 4 Statement of changes in beneficial ownership of securities

CAMBRIDGE, Mass.,Oct. 17, 2024(GLOBE NEWSWIRE) --Agios Pharmaceuticals, Inc.(Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast onThursday, October 31, 2024, at8:00 a.m. ETto report its third quarter 2024 financial results and business highlights.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website atwww.agios.com. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.

About AgiosAgios is the pioneering leader in pyruvate kinase (PK) activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In theU.S., Agios markets a first-in-class PK activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndrome (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website atwww.agios.com.

Contacts:Investor ContactChris Taylor, VP, Investor Relations and Corporate CommunicationsAgios PharmaceuticalsIR@agios.com

Media ContactEamonn Nolan, Senior Director, Corporate CommunicationsAgios Pharmaceuticalsmedia@agios.com

Primary Logo

Source: Agios Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com